Patents Examined by Jegatheesan Seharaseyon
  • Patent number: 11359022
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: June 14, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker
  • Patent number: 11359026
    Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: June 14, 2022
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.
    Inventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
  • Patent number: 11352423
    Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 7, 2022
    Assignee: MORPHOSYS AG
    Inventors: Patrick Garidel, Andreas Langer, Martin Hessling, Daniel Weinfurtner, Bodo Brocks
  • Patent number: 11345744
    Abstract: We provide new monoclonal antibody inhibitors of coagulases staphylocoagulase and vWbp for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the coagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: May 31, 2022
    Inventor: William R Church
  • Patent number: 11325979
    Abstract: The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: May 10, 2022
    Inventors: Joe Pirrello, John Paolini, Eben Tessari
  • Patent number: 11319356
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Patent number: 11319381
    Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: May 3, 2022
    Assignees: INSERM (Institut National de la Santéet de la Recherche Médicale), UniversitéPaul Sabatier Toulouse III, Institut Claudius Regaud
    Inventors: Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra
  • Patent number: 11318207
    Abstract: The present invention relates to a method for PEGylating interferon beta.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 3, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Robert S. Gronke, Orlando A. Jaquez
  • Patent number: 11305001
    Abstract: The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 19, 2022
    Assignee: The Children's Medical Center Corporation
    Inventors: Richard Malley, Fan Zhang, Yingjie Lu
  • Patent number: 11291720
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: April 5, 2022
    Assignee: AKESO BIOPHARMA, INC.
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • Patent number: 11291725
    Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of tocilizumab, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: April 5, 2022
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Jan Jezek, Luca Badiali, David Gerring
  • Patent number: 11292823
    Abstract: Fusion molecules composed of a type I interferon protein or portion thereof and a type III interferon protein or portion thereof, pharmaceutical compositions containing the fusion molecules, and methods for their use in inhibiting infection, inhibiting or treating cancer, inducing signaling of transcription of IFN-stimulated genes through an IFN-?R2 chain in a subject suffering from an infection which degrades or downregulates an IFN-?R1 chain, and treating various diseases or conditions are provided.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 5, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sergei V. Kotenko, Joan Durbin, Viralkumar Rameshkumar Davra
  • Patent number: 11285210
    Abstract: The disclosure provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, sorbitol, histidine and/or a histidine salt and optionally arginie and/or an arginine salt, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: March 29, 2022
    Assignee: Outlook Therapeutics, Inc.
    Inventors: Hiten Gutka, Maria Taddei, Jessica Cheung
  • Patent number: 11279772
    Abstract: Methods of preventing and treating type-1 diabetes and its complications using antibody activators that bind to the (Na++K+)-ATPase.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: March 22, 2022
    Inventor: Kai Yuan Xu
  • Patent number: 11275091
    Abstract: Disclosed herein are methods that employ the use of one or more biomarkers for the treatment of SARS-CoV-2 infected individuals (COVID-19 patients). The methods may employ detection and measurement of one or more cytokines, the measurement of which may be used to treat COVID-19 patients with one or more immunomodulatory therapies.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: March 15, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Gang Huang
  • Patent number: 11267883
    Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 8, 2022
    Assignee: Cephalon, Inc.
    Inventors: David Jose Simon Laine, Matthew Pollard, Anthony Gerard Doyle, Lynn Dorothy Poulton, Adam William Clarke
  • Patent number: 11246910
    Abstract: The present disclosure describes a method of treating immunological disorders, for example alloimmune and autoimmune diseases, using a pharmaceutical composition comprising at least one mesenchymal stromal cell-derived protein Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 15, 2022
    Assignee: Singapore Health Services Pte Ltd
    Inventors: Xiubo Fan, William Ying Khee Hwang, Hsiu Ling Low, Julian Thumboo, Chin Teck Ng
  • Patent number: 11248048
    Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 15, 2022
    Assignee: Y-BIOLOGICS INC.
    Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chui Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Patent number: 11246911
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 15, 2022
    Assignees: VIB VZW, Centre National de la Recherche Scientifique, Univeriteit Gent, Universite de Montpellier
    Inventors: Jan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
  • Patent number: 11242371
    Abstract: Disclosed are fusion polypeptides comprising fragments from a first and a second isoform of an interferon lambda family, nucleic acids encoding the fusion polypeptides, and vectors and host cells containing the same, and methods of making and using such compositions in treatment of interferon lambda-related diseases, disorders, and conditions.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 8, 2022
    Assignee: Prosit Sole Biotechnology (Beijing) Co, Ltd
    Inventors: Hongyu Liu, Mingzhi Zhao, Hetong Sun